Protox lines up $35M for BPH program

Warburg Pincus will invest up to $35 million in Canada's Protox Therapeutics, fueling its new therapy for benign prostatic hyperplasia as it advances into late-stage trials. The investment group will take a 21 percent stake in Protox in exchange for the first $10 million tranche. The additional money is scheduled to arrive in the next year. Story

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.